(Q33808848)

29 July 2017

1 reference

title

First trial of the HIV-1 vaccine in Africa: Ugandan experience (English)

1 reference

29 July 2017

0 references

8

Jerrold J Ellner

1 reference

29 July 2017

2

Pontiano Kaleebu

1 reference

29 July 2017

3

Peter Mugyenyi

1 reference

29 July 2017

Roy D Mugerwa

1

1 reference

29 July 2017

Edward Katongole-Mbidde

4

1 reference

29 July 2017

David L Hom

5

1 reference

29 July 2017

Rose Byaruhanga

6

1 reference

29 July 2017

Robert A Salata

7

1 reference

29 July 2017

HIV-1 Vaccine Trial Group

9

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

29 July 2017

1 reference

29 July 2017

324

1 reference

29 July 2017

226-229

1 reference

29 July 2017

7331

1 reference

Developing AIDS vaccine trials educational programs in Uganda.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

HIV-1 risk and vaccine acceptability in the Ugandan military

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

Bioethics and local circumstances

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1122137

The safety and use of canarypox vectored vaccines

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11809648

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HIV vaccine development for the world: an idea whose time has come?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11809648

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Behavioral research contributions to planning and conducting HIV vaccine efficacy studies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11809648

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/BMJ.324.7331.226

1 reference

29 July 2017

1 reference

29 July 2017

1 reference